Sawai Pharmaceuticals - Generic Company Intelligence Report

SUMMARY

The Japanese firm, Sawai Pharmaceutical, was established as Sawai Pharmacy in Asahi-ku, Osaka, in 1929. This report provides an insight into the company, reviewing its current business structure and activities.

Sawai Pharmaceutical was incorporated in 1948, and in 1961, it set up manufacturing lines for OTCs in its head office factory. In 1965, Sawai changed from an OTC manufacturer to ethical pharmaceuticals, and three years later, completed its second factory; other factories followed from the late 1980s onwards. In 1985, Sawai incorporated Medisa Shinyaku, which was set up as a wholly-owned subsidiary in 1991. The company opened its Osaka Laboratory in 1984, built a research and development centre in 1990, and opened its pharmaceutical research centre in 1994. In 1995, Sawai was listed on the OTC stock market, and in 2000, it was listed on the second section of the Tokyo Stock Exchange. In 2003, it was listed on the first section of the Tokyo Stock Exchange.

Sawai deals in the export and import, manufacturing and sales of pharmaceutical products and healthcare foods. The company claims 300 ethical pharmaceuticals, such as antibiotics, cardiovascular drugs and drugs to treat cancer, as well as OTC drugs. Sawai has area offices across Japan, in Tokyo-higashi, Tokyo-nishi, Yokohama, Kita-kanto, Joshinetsu, Hokuriku, Shizuoka, Kyoto, Kobe, Takamatsu, and Matsuyama. In addition, the company has branches in Sapporo, Sendai, Tokyo, Nagoya, Osaka, Hiroshima and Fukuoka. Sawai has alliances with Meiji Seika Kaisha, Sekisui Chemical, Nihon Schering, Fuso Pharmaceutical, Mitsubishi Pharma, and Daiichi Suntory Pharma. It employs around 500 people.le.

This report provides information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances and litigation. The company's most recent quarterly and annual financial results are illustrated with comparative figures, charts and a detailed review of the data which allows you to track the company's progress.

TABLE OF CONTENTS

• EXECUTIVE SUMMARY
• INTRODUCTION
• PRODUCTS
  • Heparin calcium, flutazolam, biperiden hydrochloride
  • Synthetic penicillin
• FINANCIAL RESULTS
  • Latest Yearly Results
    • Financial results, FY1999 - 2004 (yen millions)
    • Expenses, FY1999 - 2004 (yen millions)
  • Business forecast for the first half of FY2005
• MAJOR DEVELOPMENTS
  • Mergers, acquisitions and agreements
    • Medisa Shinyaku
    • Nihon Schering's Mobara factory
    • Japan Generic Drug Research Group
  • Litigation
    • Teprenone
• CONTACT DETAILS